Developer docs
API playgroundTry for free, no card

Search company profiles

Myonex

Full company profile

uuid0007jup

Namestring
Myonex
Legal namestring
Myonex, LLC
Websiteurl
myonex.com
Company typeenum
Private
Founded yearint
1931
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersHorsham, United States
HQ citystring
Horsham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial supply, pharmaceutical packaging services, comparator drug sourcing, compounding pharmacy services, cold chain logistics
Industry2 codes
PRIMARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution
SECONDARYIMALAIAH
Unit-Dose & Compliance Packaging (Sachets, Strip Packs, Pill Organizers)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Clinical Trial Supply Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Clinical Trial Supply Services
TypeProfessional Services
Description

Myonex provides integrated clinical trial supply services including comparator and commercial drug sourcing, clinical packaging, labeling, and distribution, pharmacy services (including compounding), and bioservices. These services are typically delivered under multi-year project contracts with pharmaceutical and biotech sponsors and CROs.

myonex.com
2Commercial Pharmaceutical Packaging Services
TypeManaged Services
Description

Contract commercial packaging services for pharma, biotech, and medical device companies including primary packaging (blistering and bottling), secondary packaging, serialization, and repackaging. Revenue generated through project-based and ongoing service agreements.

myonex.com
3Drug and Ancillary Sourcing
TypeTransaction Fee
Description

Sourcing of comparator drugs, commercial medications, and ancillary equipment and supplies for clinical trials. Myonex leverages exclusive manufacturer partnerships to provide cost savings and supply continuity for clients.

myonex.com
4Consulting Services
TypeProfessional Services
Description

Pharmacist consulting services, supply chain optimization consulting, and ultra-cold chain consulting delivered by Myonex experts. These services support clinical trial planning, execution, and cold chain management.

myonex.com
5CTRx® Solution
TypeManaged Services
Description

Prescription card services, global pharmacy dispensing, and centralized local drug supply combined into a single patient-centric solution. Eliminates upfront bulk purchasing and reduces drug waste for sponsors.

myonex.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Infrastructure, Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1CTRx
Description

A combination of prescription card services, global pharmacy dispensing, and centralized local drug supply in a single solution for clinical trials.

myonex.com
+1 more record
Core offering1 text field

Myonex provides integrated clinical trial supply and commercial pharmaceutical services to pharmaceutical sponsors, biotech companies, and CROs globally. Its offerings include drug sourcing, clinical packaging, labeling, distribution, pharmacy services (including compounding), bioservices with ultra-cold storage, commercial packaging, and consulting. The flagship solution CTRx® combines prescription card services, global pharmacy dispensing, and centralized local drug supply to reduce drug waste and trial costs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 65% cost savings in clinical trial drug supply compared to traditional central sourcing models
+3 more records
Product overview1 text field

Myonex is an integrated clinical trial supply and commercial pharmaceutical services company offering a comprehensive suite of services across the drug development lifecycle. The portfolio centers on CTRx® as the core patient-centric solution, which uniquely combines prescription card services, global pharmacy dispensing, and centralized local drug supply. Supporting services include Clinical Packaging, Labeling & Distribution for IMPs and NIMPs; Drug & Ancillary Sourcing with exclusive manufacturer partnerships; US Pharmacy Services (including SaveWay Compounding Pharmacy for sterile/non-sterile compounding and DtP capabilities); Bioservices for ultra-cold storage and ATMP supply chain management; Commercial Packaging with serialization capabilities; and Biologicals & ATMPs Supply Chain services. The consulting arm provides Pharmacist Consulting, Supply Chain Optimization (with advanced forecasting simulation), and Ultra-Cold Chain Consulting. All services are designed to reduce time, cost, and complexity for pharmaceutical, biotech, and CRO partners.

Product and service10 records
1CTRx®
CategoryClinical Trial Patient Solution
Description

Clinical trial patient solutions combining prescription card services, global pharmacy dispensing, and centralized local drug supply in a single integrated solution designed to eliminate drug waste and reduce costs.

2Clinical Packaging, Labeling & Distribution
CategoryClinical Services
Description

End-to-end clinical trial packaging, labeling, and distribution services including primary packaging (blistering, bottling), secondary packaging, JIT labeling, blinding options, and global distribution to sites or direct-to-patient.

3Drug & Ancillary Sourcing
CategoryClinical Services
Description

Comparator drug sourcing and ancillary supplies for clinical trials including exclusive manufacturer partnerships, limited distribution drugs access, REMS programs, and global depot network for pharmaceutical and biotech companies.

4Pharmacy Services (US 50-State)
CategoryClinical Services
Description

Comprehensive US pharmacy capabilities including SaveWay Compounding Pharmacy for sterile and non-sterile compounding, IMP dispensing, direct-to-patient shipping, and decentralized clinical trial support across all 50 states.

5Bioservices
CategoryClinical Services
Description

Cold and ultra-cold biostorage services for biological materials including ATMP supply chain management, cell and gene therapy logistics, biorepository, and cryopreservation from -80°C to -196°C.

6Commercial Packaging
CategoryCommercial Services
Description

Contract pharmaceutical packaging services for commercial products including primary packaging (blistering, bottling), secondary packaging, serialization, and aggregation for pharma, biotech, and medical device companies.

7Biologicals & ATMPs Supply Chain
CategoryCommercial Services
Description

Specialized cold chain storage, packaging, and logistics for biologicals and Advanced Therapy Medicinal Products (ATMPs) including immunotherapies, vaccines, CAR-T cells, and gene therapies with temperatures from 2°C-8°C to -196°C.

8Pharmacist Consulting Services
CategoryConsulting Services
Description

Expert pharmacist collaboration for clinical trial protocol navigation including pharmacy manuals, direct-to-patient operationalization, and IDS pharmacist support.

9Supply Chain Optimization Consulting
10Ultra-Cold Chain Consulting
CategoryConsulting Services
Description

Consulting, audits, and training services for biostorage and ultra-low temperature environments including cryopreservation expertise, staff training (Qualiopi certified), and biobank design support.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Myonex designed and is executing a hybrid local and central sourcing and labeling strategy for Debiopharm's Phase III trial (Debio 4126-301) across 70 sites in 20 countries. The collaboration demonstrates Myonex's integrated clinical supply capabilities, combining CTRx local sourcing, central JIT labeling, and Direct-to-Patient distribution.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-24
Description

Myonex was selected by LLS as the preferred partner to support patients participating in the LLS-sponsored Beat AML Master Clinical Trial through its CTRx solution. This partnership helps ensure uninterrupted access to commercial medications and comprehensive patient financial assistance for blood cancer patients enrolled in the trial.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-30
Description

Myonex and Adalvo have an expanded exclusive clinical trial supply partnership under which Myonex is the exclusive global provider of Adalvo products for clinical trial use. The partnership was further expanded to include multiple new assets for global markets. This partnership enables Myonex to provide pharmaceutical companies, biotechs, CROs, and other service providers with access to Adalvo's generic and biosimilar medicines for clinical trials, delivering cost reductions, supply continuity, and timely availability.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Debiopharm partnered with Myonex for the Debio 4126-301 Phase III trial, utilizing Myonex's hybrid sourcing solution combining central Just-In-Time labeling in Europe and CTRx local sourcing across 6 global countries including the US, Spain, France, UK, Brazil, and Israel.

5Strategic Depot Partner Network
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Myonex maintains a strategic partner depot network spanning countries in Europe, North America, Latin America, Asia Pacific, Middle East, and Africa to extend its storage and distribution reach beyond its owned facilities.

myonex.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UPS-owned clinical trial supply chain and logistics specialist covering drug distribution, cold chain, and Direct-to-Patient services. Comparable to Myonex's clinical distribution and bioservices capabilities, with similar sponsor base.

TypeDirect peer
Description

Contract packaging provider for pharma and biotech including clinical and commercial packaging, serialization, and compliance packaging. Directly comparable to Myonex's commercial and clinical packaging operations.

3Recipharm
TypeBroad incumbent
Description

European-headquartered CDMO offering contract development, manufacturing, and supply services to pharma and biotech. Overlaps with Myonex's commercial packaging and pharma services in Europe, particularly post-Creapharm.

TypeEmerging player
Description

Biologics-focused CDMO and pharma services firm with growing clinical and commercial capabilities. Comparable emerging player to Myonex in biologics packaging and supply services.

TypeDirect peer
Description

Global pharma services provider offering clinical and commercial supply, packaging, biologics, and cell/gene therapy services. Closest large-scale direct peer to Myonex's integrated clinical supply and commercial packaging model, though substantially larger in scale.

TypeDirect peer
Description

Contract pharma services provider specializing in clinical and commercial packaging, serialization, and global supply chain. Directly competes with Myonex across integrated packaging, labeling, and distribution services.

TypeDirect peer
Description

Privately held global contract pharma services company offering clinical trial supply, packaging, labeling, distribution, and commercial services. Closely aligned with Myonex across clinical packaging, blinding, and global distribution services.

TypeBroad incumbent
Description

Diversified life sciences incumbent whose Patheon pharma services segment spans clinical supply, commercial packaging, and CDMO capabilities. Overlaps with Myonex's clinical packaging and distribution offering but as part of a much broader portfolio.

TypeBroad incumbent
Description

Largest CRO with extensive clinical trial operations and ancillary clinical supply capabilities. Broad incumbent competing for the same pharma and biotech sponsor budgets as Myonex, though with vastly broader service breadth.

TypeBroad incumbent
Description

Diversified testing and contract pharma services group offering CDMO, packaging, and analytical services. Comparable to Myonex's commercial packaging and bioservices offerings as part of a broader services portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Myonex

Clinical Trial Supply Servicesmyonex.com

Myonex firmographics

Firmographics
Name
Myonex
Legal name
Myonex, LLC
Website
https://myonex.com
Company type
Private
Founded year
1931
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Myonex industry classification

Industry
Product category
Clinical Trial Supply Services
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution
SECONDARYIMALAIAH
Unit-Dose & Compliance Packaging (Sachets, Strip Packs, Pill Organizers)

Keywords

  • Clinical trial supply
  • Pharmaceutical packaging services
  • Comparator drug sourcing
  • Compounding pharmacy services
  • Cold chain logistics

Where Myonex is headquartered

Location

Headquarters

HQ city
Horsham
HQ country
United States
HQ region
North America

Offices7 records

Markets served

Myonex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Infrastructure, Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

  1. Clinical Trial Supply Services: Myonex provides integrated clinical trial supply services including comparator and commercial drug sourcing, clinical packaging, labeling, and distribution, pharmacy services (including compounding), and bioservices. These services are typically delivered under multi-year project contracts with pharmaceutical and biotech sponsors and CROs.
  2. Commercial Pharmaceutical Packaging Services: Contract commercial packaging services for pharma, biotech, and medical device companies including primary packaging (blistering and bottling), secondary packaging, serialization, and repackaging. Revenue generated through project-based and ongoing service agreements.
  3. Drug and Ancillary Sourcing: Sourcing of comparator drugs, commercial medications, and ancillary equipment and supplies for clinical trials. Myonex leverages exclusive manufacturer partnerships to provide cost savings and supply continuity for clients.
  4. Consulting Services: Pharmacist consulting services, supply chain optimization consulting, and ultra-cold chain consulting delivered by Myonex experts. These services support clinical trial planning, execution, and cold chain management.
  5. CTRx® Solution: Prescription card services, global pharmacy dispensing, and centralized local drug supply combined into a single patient-centric solution. Eliminates upfront bulk purchasing and reduces drug waste for sponsors.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Myonex product offering

Product offering

Core offering

Myonex provides integrated clinical trial supply and commercial pharmaceutical services to pharmaceutical sponsors, biotech companies, and CROs globally. Its offerings include drug sourcing, clinical packaging, labeling, distribution, pharmacy services (including compounding), bioservices with ultra-cold storage, commercial packaging, and consulting. The flagship solution CTRx® combines prescription card services, global pharmacy dispensing, and centralized local drug supply to reduce drug waste and trial costs.

Product overview

Myonex is an integrated clinical trial supply and commercial pharmaceutical services company offering a comprehensive suite of services across the drug development lifecycle. The portfolio centers on CTRx® as the core patient-centric solution, which uniquely combines prescription card services, global pharmacy dispensing, and centralized local drug supply. Supporting services include Clinical Packaging, Labeling & Distribution for IMPs and NIMPs; Drug & Ancillary Sourcing with exclusive manufacturer partnerships; US Pharmacy Services (including SaveWay Compounding Pharmacy for sterile/non-sterile compounding and DtP capabilities); Bioservices for ultra-cold storage and ATMP supply chain management; Commercial Packaging with serialization capabilities; and Biologicals & ATMPs Supply Chain services. The consulting arm provides Pharmacist Consulting, Supply Chain Optimization (with advanced forecasting simulation), and Ultra-Cold Chain Consulting. All services are designed to reduce time, cost, and complexity for pharmaceutical, biotech, and CRO partners.

Differentiator

Problem solved

Functional benefit

Brands

  • CTRx: A combination of prescription card services, global pharmacy dispensing, and centralized local drug supply in a single solution for clinical trials.
  • myCTcentral

Products and services

  • CTRx® Clinical trial patient solutions combining prescription card services, global pharmacy dispensing, and centralized local drug supply in a single integrated solution designed to eliminate drug waste and reduce costs.
  • Clinical Packaging, Labeling & Distribution End-to-end clinical trial packaging, labeling, and distribution services including primary packaging (blistering, bottling), secondary packaging, JIT labeling, blinding options, and global distribution to sites or direct-to-patient.
  • Drug & Ancillary Sourcing Comparator drug sourcing and ancillary supplies for clinical trials including exclusive manufacturer partnerships, limited distribution drugs access, REMS programs, and global depot network for pharmaceutical and biotech companies.
  • Pharmacy Services (US 50-State) Comprehensive US pharmacy capabilities including SaveWay Compounding Pharmacy for sterile and non-sterile compounding, IMP dispensing, direct-to-patient shipping, and decentralized clinical trial support across all 50 states.
  • Bioservices Cold and ultra-cold biostorage services for biological materials including ATMP supply chain management, cell and gene therapy logistics, biorepository, and cryopreservation from -80°C to -196°C.
  • Commercial Packaging Contract pharmaceutical packaging services for commercial products including primary packaging (blistering, bottling), secondary packaging, serialization, and aggregation for pharma, biotech, and medical device companies.
  • Biologicals & ATMPs Supply Chain Specialized cold chain storage, packaging, and logistics for biologicals and Advanced Therapy Medicinal Products (ATMPs) including immunotherapies, vaccines, CAR-T cells, and gene therapies with temperatures from 2°C-8°C to -196°C.
  • Pharmacist Consulting Services Expert pharmacist collaboration for clinical trial protocol navigation including pharmacy manuals, direct-to-patient operationalization, and IDS pharmacist support.
  • Supply Chain Optimization Consulting
  • Ultra-Cold Chain Consulting Consulting, audits, and training services for biostorage and ultra-low temperature environments including cryopreservation expertise, staff training (Qualiopi certified), and biobank design support.

Quantifiable outcome

  • Up to 65% cost savings in clinical trial drug supply compared to traditional central sourcing models
  • +3 more outcomes

Companies that use Myonex

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Myonex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Myonex partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • DebiopharmcoreStrategic or Co-development Partner · 1 December 2025Myonex designed and is executing a hybrid local and central sourcing and labeling strategy for Debiopharm's Phase III trial (Debio 4126-301) across 70 sites in 20 countries. The collaboration demonstrates Myonex's integrated clinical supply capabilities, combining CTRx local sourcing, central JIT labeling, and Direct-to-Patient distribution.
  • The Leukemia & Lymphoma Society (LLS)coreStrategic or Co-development Partner · 24 June 2025Myonex was selected by LLS as the preferred partner to support patients participating in the LLS-sponsored Beat AML Master Clinical Trial through its CTRx solution. This partnership helps ensure uninterrupted access to commercial medications and comprehensive patient financial assistance for blood cancer patients enrolled in the trial.
  • AdalvocoreStrategic or Co-development Partner · 30 October 2024Myonex and Adalvo have an expanded exclusive clinical trial supply partnership under which Myonex is the exclusive global provider of Adalvo products for clinical trial use. The partnership was further expanded to include multiple new assets for global markets. This partnership enables Myonex to provide pharmaceutical companies, biotechs, CROs, and other service providers with access to Adalvo's generic and biosimilar medicines for clinical trials, delivering cost reductions, supply continuity, and timely availability.
  • DebiopharmcoreStrategic or Co-development PartnerDebiopharm partnered with Myonex for the Debio 4126-301 Phase III trial, utilizing Myonex's hybrid sourcing solution combining central Just-In-Time labeling in Europe and CTRx local sourcing across 6 global countries including the US, Spain, France, UK, Brazil, and Israel.
  • Strategic Depot Partner NetworkminorChannel Partner/ Reseller/ DistributorMyonex maintains a strategic partner depot network spanning countries in Europe, North America, Latin America, Asia Pacific, Middle East, and Africa to extend its storage and distribution reach beyond its owned facilities.

Scale indicators10 records

Recent moves10 records

Expansion highlights6 records

Myonex competitors and assessment

Company assessment

Direct peers

  • Marken (UPS Healthcare): UPS-owned clinical trial supply chain and logistics specialist covering drug distribution, cold chain, and Direct-to-Patient services. Comparable to Myonex's clinical distribution and bioservices capabilities, with similar sponsor base.
  • Sharp Packaging (Clinigen): Contract packaging provider for pharma and biotech including clinical and commercial packaging, serialization, and compliance packaging. Directly comparable to Myonex's commercial and clinical packaging operations.
  • Catalent: Global pharma services provider offering clinical and commercial supply, packaging, biologics, and cell/gene therapy services. Closest large-scale direct peer to Myonex's integrated clinical supply and commercial packaging model, though substantially larger in scale.
  • PCI Pharma Services: Contract pharma services provider specializing in clinical and commercial packaging, serialization, and global supply chain. Directly competes with Myonex across integrated packaging, labeling, and distribution services.
  • Almac Group: Privately held global contract pharma services company offering clinical trial supply, packaging, labeling, distribution, and commercial services. Closely aligned with Myonex across clinical packaging, blinding, and global distribution services.

Broad incumbents

  • Recipharm: European-headquartered CDMO offering contract development, manufacturing, and supply services to pharma and biotech. Overlaps with Myonex's commercial packaging and pharma services in Europe, particularly post-Creapharm.
  • Thermo Fisher Scientific (Patheon/CDMO): Diversified life sciences incumbent whose Patheon pharma services segment spans clinical supply, commercial packaging, and CDMO capabilities. Overlaps with Myonex's clinical packaging and distribution offering but as part of a much broader portfolio.
  • IQVIA: Largest CRO with extensive clinical trial operations and ancillary clinical supply capabilities. Broad incumbent competing for the same pharma and biotech sponsor budgets as Myonex, though with vastly broader service breadth.
  • Eurofins CDMO: Diversified testing and contract pharma services group offering CDMO, packaging, and analytical services. Comparable to Myonex's commercial packaging and bioservices offerings as part of a broader services portfolio.

Emerging players

  • Bionova Scientific: Biologics-focused CDMO and pharma services firm with growing clinical and commercial capabilities. Comparable emerging player to Myonex in biologics packaging and supply services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Myonex social profiles

Digital presence

Myonex compliance and trust

Trust signal

Compliance9 records

Myonex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Myonex leadership team

Management profile

Number of profiles

Profiles11 records

Myonex subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Myonex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Myonex M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myonex

What does Myonex do?

Myonex provides integrated clinical trial supply and commercial pharmaceutical services to pharmaceutical sponsors, biotech companies, and CROs globally. Its offerings include drug sourcing, clinical packaging, labeling, distribution, pharmacy services (including compounding), bioservices with ultra-cold storage, commercial packaging, and consulting. The flagship solution CTRx® combines prescription card services, global pharmacy dispensing, and centralized local drug supply to reduce drug waste and trial costs.

Is Myonex a public or private company?

Myonex is a private company. It is classified as family owned and is currently operating.

When was Myonex founded?

Myonex was founded in 1931. It employs 251 to 500 people.

Where is Myonex based?

Myonex is headquartered in Horsham, United States, in the North America region.

How does Myonex make money?

Five revenue lines are on record. Clinical Trial Supply Services are the primary driver. The others are commercial Pharmaceutical Packaging Services, drug and Ancillary Sourcing, consulting Services and CTRx® Solution.

Who are Myonex's main competitors?

Direct peers on record are Marken (UPS Healthcare), Sharp Packaging (Clinigen), Catalent, PCI Pharma Services and Almac Group. Broad incumbents are Recipharm, Thermo Fisher Scientific (Patheon/CDMO), IQVIA and Eurofins CDMO. Bionova Scientific is listed as an emerging player.

Does Myonex have an API?

No public API is recorded for Myonex.

What industry is Myonex in?

Myonex's product category is Clinical Trial Supply Services. Its primary akta.pro industry code is CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution, with a secondary code of IMALAIAH, Unit-Dose & Compliance Packaging (Sachets, Strip Packs, Pill Organizers). Its NAICS code is 32541 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comCompounding Pharmacy Market to Surpass US$ 26.8 Billion by 2034 Driven by Personalized Medicine and Rising Demand for Customized TherapiesThe global compounding pharmacy market is projected to grow from US$ 13,474.6 million in 2023 to US$ 26,838.8 million by 2034, expanding at a CAGR of 6.5%, driven by personalized medicine demand, rising chronic disease prevalence, and customized drug formulations. Key market developments include Myonex's acquisition of Saveway Compounding Pharmacy in April 2024 and Precision Compounding Pharmacy's seed investment from Right Side Capital Management in November 2023. Despite growth prospects, the market faces challenges from strict regulatory requirements, quality control concerns, and safety issues related to improper compounding.openPR.comAnalysis of Key Market Segments Influencing the Clinical Trial Supplies MarketThe clinical trial supplies market is projected to reach $4.33 billion by 2030, growing at a compound annual growth rate of 8.7%, driven by increasing trial complexity, decentralized trial models, and heightened regulatory oversight. Key industry players including Thermo Fisher Scientific, IQVIA, Catalent, and over 20 other companies are identified as dominant market forces in this sector. A notable transaction occurred in May 2024 when US-based Myonex acquired France-headquartered Creapharm's pharmaceutical services business, expanding Myonex's clinical and commercial packaging capabilities.BioSpaceMyonex Appoints Greg Lavin as Chief Executive OfficerMyonex announced the appointment of Greg Lavin as Chief Executive Officer, effective January 1, 2026, succeeding James Lovett who is retiring after leading the company since July 2019. Lavin, who has served as CFO for over six years, will continue to drive the company's transformation from a comparator sourcing supplier to an integrated clinical trial supply and commercial packaging services provider. Under Lovett's tenure, Myonex expanded through strategic acquisitions including Hubertus Apotheke in Germany, SaveWay Compounding Pharmacy in Delaware, and Creapharm Bio & Pharma in France.YahooClinical Trial Equipment & Ancillary Solutions Market to Reach USD 4.39 Billion by 2032, Driven by Rising Trial Volume – SNS InsiderThe global Clinical Trial Equipment & Ancillary Solutions market was valued at USD 2.23 billion in 2023 and is projected to reach USD 4.39 billion by 2032, growing at a CAGR of 7.84%, driven by increasing trial complexity, R&D spending, and adoption of decentralized trial models. North America led the market with a 40.05% revenue share in 2023, while Asia Pacific is expected to be the fastest-growing region through 2032. Key recent developments include Ancillare launching advanced Cold Chain Management services in January 2025 and Myonex acquiring Creapharm's Clinical & Commercial Packaging and Bioservices business in March 2024, expanding its operations in France and Georgia, USA.BioSpaceCompounding Pharmacies Market Size to Hit USD 33.73 Billion by 2034A market research report projects the global compounding pharmacies market will grow from USD 17.31 billion in 2024 to USD 33.73 billion by 2034, representing a CAGR of 6.9%. North America led the market in 2024 with a 49.11% share, while the pain management segment accounted for 34.86% of revenues. The report highlights two notable acquisitions: Myonex's purchase of Saveway Compounding Pharmacy in April 2024 and Grey Wolf Animal Health Corp's acquisition of the Compounding Pharmacy of Manitoba for $22.5 million in December 2024.BioSpaceCompounding Pharmacy Market to Hit US$ 31.77 Billion by 2034The global compounding pharmacy market was valued at US$15.89 billion in 2023 and is projected to reach US$31.77 billion by 2034, growing at a CAGR of 6.5%, driven by increasing reliance of hospitals and medical practices on customized drugs when FDA-approved medications are unavailable. North America captured 44.13% of revenue share in 2023, with approximately 56,000 community-based pharmacies in the U.S., of which about 7,500 offer dedicated compounding services, while Europe holds a significant share supported by a robust regulatory framework. Key market dynamics include growth in personalized medicine, sterile compounding demand, and acquisitions such as Myonex acquiring Saveway Compounding Pharmacy in April 2024 and Medios acquiring the Dutch market leader in March 2024.PR NewswireMYONEX SCHLIESST DIE ÜBERNAHME VON CREAPHARM AB UND ERWEITERT DIE WELTWEITEN DIENSTLEISTUNGENMyonex has completed the acquisition of Creapharm's pharmaceutical services business, combining clinical packaging, distribution, commercial packaging, and bioservices operations. The transaction enables Myonex to serve pharmaceutical and biotech companies across both clinical and commercial phases, including companies managing advanced therapies, with expanded cold chain management capabilities. Creapharm will now operate as a Myonex company, with founder Eric Placet joining Myonex's board of directors.PR NewswireMYONEX CONCLUT L'ACQUISITION DE CREAPHARM ET ÉTEND SES SERVICES MONDIAUXMyonex has finalized its previously announced acquisition of Creapharm's pharmaceutical services business, combining clinical packaging, distribution, and bioservices capabilities for pharmaceutical and biotech companies at clinical and commercial stages. Creapharm will now operate as a subsidiary under the Myonex umbrella, with operations spanning the United States, Germany, and the United Kingdom. The leadership transition includes founder Eric Placet joining Myonex's board of directors and Carla Da Costa appointed as chief operating officer, while Edouard Placet continues as director of strategic development.PR NewswireMYONEX CIERRA LA ADQUISICIÓN DE CREAPHARM AMPLIANDO LOS SERVICIOS GLOBALESMyonex has completed its previously announced acquisition of Creapharm's pharmaceutical services business, combining capabilities to serve pharmaceutical and biotech companies across clinical and commercial stages, including advanced therapies. The acquired distribution, clinical packaging, commercial packaging operations, and bioservices will now operate under Creapharm, a Myonex company. Founder Eric Placet joins Myonex's board of directors, and Carla Da Costa has been appointed as chief operating officer as part of the executive strengthening.PR NewswireMYONEX CLOSES CREAPHARM ACQUISITION EXPANDING GLOBAL SERVICESMyonex has completed its acquisition of CREAPHARM's pharmaceutical services business, combining their capabilities to serve pharmaceutical and biotech companies in clinical and commercial stages. As part of the deal, Eric Placet joined Myonex's Board of Directors while retaining his role at CREAPHARM, which will now operate as a Myonex company. The transaction was supported by legal and financial advisors from both firms.